Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trialCaicun Zhou, Jianjun Zou, Fengying Wu et al.|The Lancet Respiratory Medicine|2020Cited by 504
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 TrialShengxiang Ren, Caicun Zhou, Jianhua Chen et al.|Journal of Thoracic Oncology|2021Cited by 311
Synergistic effects of combined treatment with simvastatin and exemestane on MCF-7 human breast cancer cellsYuanyuan Shen, Yueyin Pan|Molecular Medicine Reports|2012Cited by 22
MicroRNA‑26a inhibits cell proliferation and invasion by targeting FAM98A in breast cancerTan Liu, Yueyin Pan|Oncology Letters|2021Cited by 19
LBA12 Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Initial results from a registrational phase II studyQing Zhou, Yi‐Long Wu, Xue Meng et al.|Annals of Oncology|2023Cited by 10